Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Related Keywords

Samer Zeidan , Division Of Hematologic Malignancies , Hematologic Malignancies , Hematology Early Therapeutics Research , Yale Cancer Center , Ziftomenib , Phase 1 2 Komet 007 Trial , Nct04067336 , Aml , Acute Myeloid Leukemia , Npm1 Mutant And Kmt2a Rearranged , Npm1 Mutant And Kmt2a Rearranged Aml , Venclexta , Vidaza , Azacitidine , Venetoclax , Cytarabine And Daunorubicin 7 3 ,